Polyphron raises $20M to test drugs on lab-grown human heart tissue

Polyphron has raised $20 million to scale an automated foundry that grows living human heart tissue and uses it to predict drug toxicity before clinical trials. The round was first reported by AlleyWatch.

Founder Matthew Osman began the project after an MRI in late 2023 revealed a pancreatic mass that proved benign, leaving him to question why medicine still cannot reliably forecast what happens inside the human body. The company’s platform trains AI models on physiological responses observed in its engineered tissue, aiming to reduce late-stage trial failures caused by unexpected toxicity.

The approach contrasts with earlier AI-driven drug-discovery startups that focus on generating novel molecules or optimizing trial design. When we covered Cori Clinical’s $4 million seed in October, the emphasis was on cutting trial delays through better patient recruitment and protocol design. Polyphron, by contrast, is building the biological substrate itself—an automated system that produces consistent, scalable human tissue for repeated testing.

The $20 million round suggests investors are betting that the real bottleneck in AI-driven biology is not idea generation but the ability to validate those ideas against living human systems. If successful, the company could lower the cost of preclinical testing by replacing animal models with reproducible human tissue, potentially accelerating the path to first-in-human studies. No lead investor or valuation was disclosed.

Sources: alleywatch.com